One of the well known contract research and manufacturing services (CRAMS) pharmaceutical companies in India, Jubilant Organosys has signed up a joint venture agreement with US multinational drug major firm, Eli Lilly in order to offer development services in drugs to each other.
The joint venture, which will start operationalising before the end of this year, is on similar lines as Chorus, Eli Lilly’s early-stage development division.
Chorus provides fast drug development services to Eli Lilly by roping in external contract research specialists for specific areas of drug development.